Microvesicles (MVs) are extracellular vesicles released by cells following activation or apoptosis. Some MV subpopulations augment with cirrhosis severity and contribute to portal hypertension. This study aimed at determining if plasma MV levels can estimate the presence of hepatic venous pressure gradient (HVPG) ≥10 mm Hg and predict mortality in patients with advanced chronic liver disease. All patients with severe fibrosis or cirrhosis undergoing liver catheterization between 2013 and 2015 at two centers were prospectively included. We measured circulating levels of annexin V+ , platelet, leukocyte, endothelial, and hepatocyte MVs. The test cohort included 139 patients. Hepatocyte MV levels were 4.0-fold and 2.2-fold higher in patients with Child-Pugh C than in those with Child-Pugh A or B liver disease, respectively. Levels of other MV subpopulations were not influenced by liver disease severity. Hepatocyte MV levels correlated with HVPG but could not identify patients with HVPG ≥10 mm Hg. Hepatocyte MV level >65 U/L predicted 6-month mortality independently of Child-Pugh score and of Model for End-Stage Liver Disease (MELD). Patients with hepatocyte MV levels >65 U/L and MELD >15 had a higher 6-month mortality than other patients (23% versus 3%; P = 0.001). These findings were confirmed in a validation cohort including 103 patients. CONCLUSION: Circulating MV levels cannot identify patients with HVPG ≥10 mm Hg; by contrast, hepatocyte MV levels strongly improve prediction of 6-month mortality in patients with advanced chronic liver disease; therapies associated with decreased levels of circulating hepatocyte MV might be attractive strategies in patients with severe cirrhosis. (Hepatology 2018).
Microvesicles (MVs) are extracellular vesicles released by cells following activation or apoptosis. Some MV subpopulations augment with cirrhosis severity and contribute to portal hypertension. This study aimed at determining if plasma MV levels can estimate the presence of hepatic venous pressure gradient (HVPG) ≥10 mm Hg and predict mortality in patients with advanced chronic liver disease. All patients with severe fibrosis or cirrhosis undergoing liver catheterization between 2013 and 2015 at two centers were prospectively included. We measured circulating levels of annexin V+ , platelet, leukocyte, endothelial, and hepatocyte MVs. The test cohort included 139 patients. Hepatocyte MV levels were 4.0-fold and 2.2-fold higher in patients with Child-Pugh C than in those with Child-Pugh A or B liver disease, respectively. Levels of other MV subpopulations were not influenced by liver disease severity. Hepatocyte MV levels correlated with HVPG but could not identify patients with HVPG ≥10 mm Hg. Hepatocyte MV level >65 U/L predicted 6-month mortality independently of Child-Pugh score and of Model for End-Stage Liver Disease (MELD). Patients with hepatocyte MV levels >65 U/L and MELD >15 had a higher 6-month mortality than other patients (23% versus 3%; P = 0.001). These findings were confirmed in a validation cohort including 103 patients. CONCLUSION: Circulating MV levels cannot identify patients with HVPG ≥10 mm Hg; by contrast, hepatocyte MV levels strongly improve prediction of 6-month mortality in patients with advanced chronic liver disease; therapies associated with decreased levels of circulating hepatocyte MV might be attractive strategies in patients with severe cirrhosis. (Hepatology 2018).
Authors: Nicolò Manicardi; Anabel Fernández-Iglesias; Laia Abad-Jordà; Felix Royo; Mikel Azkargorta; Martí Ortega-Ribera; David Sanfeliu-Redondo; Ana Martínez-Alcocer; Felix Elortza; Amelia J Hessheimer; Constantino Fondevila; Juan José Lozano; Juan Carlos García-Pagán; Jaime Bosch; Francisco Javier Cubero; Agustín Albillos; Javier Vaquero; Juan M Falcón-Pérez; Jordi Gracia-Sancho Journal: Cancers (Basel) Date: 2021-05-29 Impact factor: 6.639
Authors: Esperanza Gonzalez; Mikel Azkargorta; Clara Garcia-Vallicrosa; Janire Prieto-Elordui; Felix Elortza; Sonia Blanco-Sampascual; Juan Manuel Falcon-Perez Journal: Int J Biol Sci Date: 2021-05-05 Impact factor: 6.580
Authors: Yasuhiko Nakao; Pouya Amrollahi; Gopanandan Parthasarathy; Amy S Mauer; Tejasav S Sehrawat; Patrick Vanderboom; K Sreekumaran Nair; Kazuhiko Nakao; Alina M Allen; Tony Y Hu; Harmeet Malhi Journal: Nanomedicine Date: 2021-06-24 Impact factor: 6.096
Authors: Davide Povero; Hirokazu Yamashita; Wenhua Ren; Mani G Subramanian; Robert P Myers; Akiko Eguchi; Douglas A Simonetto; Zachary D Goodman; Stephen A Harrison; Arun J Sanyal; Jaime Bosch; Ariel E Feldstein Journal: Hepatol Commun Date: 2020-07-03
Authors: Gersina Rega-Kaun; Dorothea Ritzel; Christoph Kaun; Benjamin Ebenbauer; Barbara Thaler; Manfred Prager; Svitlana Demyanets; Johann Wojta; Philipp J Hohensinner Journal: Int J Mol Sci Date: 2019-04-30 Impact factor: 5.923